KRAS and cancer: By taking advantage of nonfunctional SIAH3 as a putative endogenous SIAH inhibitor, we may be able to develop a novel anti-SIAH1 and anti-SIAH2 strategy by utilizing SIAH3 expression to antagonize oncogenic K-RAS-driven metastatic human cancer cells.